Sign in

Private company

Veloxis Pharmaceuticals

Logo: http://ir.veloxis.com/static-files/6d32b377-2062-4471-9afd-d8743f1c08fd, Non-free logo, via Wikipedia4

Pharmaceutical company

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Hørsholm, Denmark, with an office in Cary, North Carolina.2 Its revenue was DKK 14.2 million.1 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

Mar 21, 2002Founded1
  • HeadquartersAmerika Plads1
  • Websitewww.veloxis.com
  • Legal formaktieselskab1
  • Listed onNasdaq Copenhagen A/S (VELO)1
  • LEI5493003DUEOIW0NPT7363
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressGdanskgade 18, 2150 Nordhavn, Denmark3
  • Registered withDanish Business Authority, 265277673

See how the biggest companies compare on our leaderboards

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Hørsholm, Denmark, with an office in Cary, North Carolina.2

Corporate structure

Veloxis Pharmaceuticals is part of a group headed by Asahi Kasei Pharma Denmark A/S. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0). Each entity in the chart links to its source.

Products and brands

MeltDose Technology Platform

MeltDose works by incorporating a drug substance with low water solubility into a "meltable" vehicle. It is then sprayed on an inert particulate carrier using fluid bed equipment.

The melt is solidified when deposed on a particle carrier, and thus captures the active drug in a solid dispersion either as a solid solution or in a nano-crystalline state. The particle size is then increased by controlling and optimizing the product temperature and feed rate of the melt.

The granulate can be directly compressed into tablets without additional processing steps besides blending with a lubricant. In addition, the technology allows for customization of the release profile.

Once in tablet form, the dissolution profile and the particle size of drugs manufactured using MeltDose® technology remain stable allowing for a long shelf-life.

Read the full text

Product Pipeline

Source:

LCP-Tacro (tacrolimus) is a once-daily dosage version of tacrolimus for prevention of rejection in organ transplant patients in two Phase 3 clinical trials in kidney transplant patients. The first study in stable transplant patients showed that LCP-Tacro was non-inferior in efficacy and safety compared to twice-daily tacrolimus (Prograf®) [ESOT REF]. The second Phase 3 clinical trial in de novo patients is ongoing. A Phase 3b clinical trial evaluating whether patients experiencing symptomatic tremor on twice-daily tacrolimus demonstrate improvement in their tremors when switched to LCP-Tacro was published in 2017, and demonstrated that LCP-Tacro resulted in improvements on a number of patient-reported outcomes.

FENOGLIDE (fenofibrate) for dyslipidemia, marketed in the U.S. by Santarus, Inc.

From Wikipedia’s article on Veloxis Pharmaceuticals, shared under CC BY-SA 4.0.5

Subsidiaries and ownership

Owners

Parent company (GLEIF)

From Wikidata.1 Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Timeline

  1. Oct 21, 2024Parent Directly consolidated by Asahi Kasei Pharma Denmark A/S3
  2. Mar 21, 2002Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5